These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 11555603)
1. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603 [TBL] [Abstract][Full Text] [Related]
2. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Plonowski A; Schally AV; Nagy A; Sun B; Halmos G Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505 [TBL] [Abstract][Full Text] [Related]
4. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557 [TBL] [Abstract][Full Text] [Related]
5. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448 [TBL] [Abstract][Full Text] [Related]
7. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. Szereday Z; Schally AV; Szepeshazi K; Bajo AM; Hebert F; Halmos G; Nagy A Int J Oncol; 2003 May; 22(5):1141-6. PubMed ID: 12684683 [TBL] [Abstract][Full Text] [Related]
8. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice. Weckbecker G; Raulf F; Bodmer D; Bruns C Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482 [TBL] [Abstract][Full Text] [Related]
9. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629 [TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524 [TBL] [Abstract][Full Text] [Related]
12. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215. Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692 [TBL] [Abstract][Full Text] [Related]
13. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077 [TBL] [Abstract][Full Text] [Related]
14. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers. Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032 [TBL] [Abstract][Full Text] [Related]
15. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Bajo AM; Schally AV; Halmos G; Nagy A Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166 [TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. Pozsgai E; Schally AV; Halmos G; Rick F; Bellyei S Horm Metab Res; 2010 Oct; 42(11):781-6. PubMed ID: 20665426 [TBL] [Abstract][Full Text] [Related]
17. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045 [TBL] [Abstract][Full Text] [Related]
18. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. Fueger BJ; Hamilton G; Raderer M; Pangerl T; Traub T; Angelberger P; Baumgartner G; Dudczak R; Virgolini I J Nucl Med; 2001 Dec; 42(12):1856-62. PubMed ID: 11752085 [TBL] [Abstract][Full Text] [Related]
19. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer]. Hofsli E Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977 [TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]